Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Neuron-targeted caveolin-1 overexpression attenuates cognitive loss and pathological transcriptome changes in symptomatic Alzheimer’s disease models

Fig. 1The alternative text for this image may have been generated using AI.

Direct hippocampal delivery of SynCav1 at symptomatic stage protects learning and memory in PSAPP mice. a Schematic of the experimental design. b Representative immunofluorescence image of Cav-1 (red) from SynCav1-injected brain. Scale bar = 1000 µm. c Schematic for classical fear conditioning protocol. d–f Assessment of fear memory acquisition, contextual memory recall, and cued memory recall performed at 12 m (6 m post SynCav1 delivery). Data are presented as percent (%) freezing mean ± SEM. Data were analyzed using two-way analysis of variance (ANOVA) followed by Fisher’s LSD multiple comparisons tests (Day 1) or One-way ANOVA (Day 2 and Day 3). n = ~20 per group. g–i Assessment of general motor function and anxiety-like behavior by open field test at 12 m. Analysis of time spent in the center area, total distance moved, and velocity. Data were presented as mean ± SEM and analyzed using One-way ANOVA. n = ~20 per group. Significance was assumed when p < 0.05. **p < 0.01, ***p < 0.005

Back to article page